Vistagen Therapeutics Inc (VTGN)
0.58
+4.27%
Vistagen Therapeutics Inc (VTGN) is currently trading at $0.58. This represents a gain of 4.27% from the previous session. With a market capitalization of $0.02B, VTGN is a key component of the Health Care sector. Investors looking to trade VTGN should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Get 15 Free Stocks on Moomoo →
T&Cs Apply. Trade VTGN commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Vistagen Therapeutics Inc (VTGN) shows a bullish trend. Analysts are watching the 0.59 level closely.
Fundamentals
Mkt Cap0.02B
P/E Ratio0.0000
Volume425,677
60-Day Technical Chart
Advanced Charting
Need more indicators for VTGN? Use the world's #1 platform.
Open VTGN on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $1
| Metric |
VTGN +4.27% |
TNYA -1.55% |
NXXT +10.76% |
ARAY +1.18% |
|---|---|---|---|---|
| Price | $0.58 | $0.60 | $0.63 | $0.60 |
| Mkt Cap | $0.02B | $0.13B | $0.08B | $0.07B |
| - | View → | View → | View → |
Latest Headlines
Vistagen CEO to give corporate overview at TD Cowen healthcare event
Stock Titan • Feb 25, 2026
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
PR Newswire • Feb 21, 2026
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen
GlobeNewswire • Feb 21, 2026
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
Yahoo Finance • Nov 13, 2025
Vistagen stock plummets after failed anxiety treatment trial
Investing.com • Dec 17, 2025
● Gemini Agentic AI Analyst Insight for VTGN
Market Education
- What do these rich Traders do - Peek into their day Jul 15, 2023
- 10 rules of money - Follow this and you are set for life Jul 16, 2023
- What Wolves Can Teach Us About Winning in the Markets Sep 8, 2025
External Research